Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDK8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK8/Cyclin C Complex Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9 Insect Cell expressed for native phosphorylation and complex assembly. |
View CDK8 Products |
| Gene Delivery | CDK8 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target engagement assays. |
View CDK8 Products |
| Benchmark Ab | Anti-CDK8 Recombinant Antibody Recombinant positive control for immunoprecipitation and western blot validation. |
View CDK8 Products |
| Validator | CDK8 siRNA Set For knockdown verification and phenotype rescue assays. |
View CDK8 Products |
| Related Target A | CDK19 Highly homologous kinase (91% identity in kinase domain) required for counter-screening to ensure drug selectivity. |
View CDK19 Products |
| Related Target B | CCNC (Cyclin C) Obligate activation partner for CDK8; essential for reconstituting active kinase complexes in vitro. |
View CCNC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Homology Off-Target Screening (CDK8 vs CDK19) | High-purity recombinant CDK8/Cyclin C and CDK19/Cyclin C complexes strictly verified by mass spectrometry and sequence analysis. |
| Structural Integrity of Intracellular Complexes | Co-expressed CDK8/Cyclin C heterodimers in Sf9 insect cells, ensuring correct folding and stoichiometric ratio. |
| Lack of Controls | Clinical Benchmark Antibodies and sequence-verified reference inhibitors included |
| False Positives in Knockdown Studies | Validated siRNA sets included for target-specific transcript depletion and specificity validation |
Live CDK8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDK8 therapeutics is intensifying, with major players shifting focus from traditional non-selective pan-CDK inhibitors to highly selective CDK8/19 small molecule modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting transcription-regulating kinases to overcome resistance to standard chemotherapies and checkpoint inhibitors.
CDK8, as a key component of the Mediator complex, does not regulate the cell cycle directly like CDK1, CDK2, CDK4, or CDK6. Instead, it acts as a transcriptional regulator. This unique mechanism of action makes it a highly attractive target in acute myeloid leukemia (AML), colorectal cancer, and advanced solid tumors, where CDK8 drives oncogenic transcriptional programs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Ryvu Therapeutics, Biocad | AML, MDS, Colorectal Cancer | Selectivity Assay (Need CDK8/Cyclin C vs CDK19/Cyclin C and pan-CDK proteins) |
| PROTAC (Degrader) | Academic / Biotech Consortia | Prostate Cancer, Solid Tumors | Ternary Complex Formation (Need high-purity CDK8/Cyclin C and sequence-verified antibodies) |
| Combination Therapy | Clinical Stage Biotechs | Immunotherapy-Resistant Tumors | Target Engagement Verification (Need Lentivirus for stable cell line expression) |